Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)
EICHORPublic-registry site landscape for NCT07707141, “Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis”, a Psoriasis study sponsored by Newsoara Biopharma Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07707141 (registry record) |
| Study title | Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of Oral HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis |
| Sponsor | Newsoara Biopharma Co., Ltd. |
| Condition(s) | Psoriasis |
| Phase | PHASE2 |
| Listed sites | 8 |
| Site countries | China |
At Beijing Friendship Hospital, Capital Medical University — one of the facilities listed on this trial — 1 other study is actively recruiting Psoriasis patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07707141.
Eichor generates a preliminary site-risk snapshot for NCT07707141 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →